Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

17.2%

5 terminated/withdrawn out of 29 trials

Success Rate

68.8%

-17.8% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

9%

1 of 11 completed trials have results

Key Signals

7 recruiting1 with results

Enrollment Performance

Analytics

N/A
9(52.9%)
Phase 2
5(29.4%)
Phase 1
2(11.8%)
Phase 3
1(5.9%)
17Total
N/A(9)
Phase 2(5)
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials
NCT07429344Recruiting

EASY Algorithm Trial (Elbow Trauma Assessment Using Sonography in Children and Youth) Diagnostic Accuracy and Safety of Point-of-care Ultrasound as a Screening Tool for Suspected Elbow Fractures in Children Aged 5 to 15 Years: a Multicenter Prospective Cohort Study

Role: collaborator

NCT04975594Active Not Recruiting

Statin-Intolerance Registry

Role: collaborator

NCT06317181Not ApplicableRecruiting

Assessment of Liver Diseases Using a Deep-Learning Approach Based on Ultrasound RF-Data

Role: collaborator

NCT05152238Recruiting

ITP Registry and Accompanying Biospecimen Collection

Role: collaborator

NCT06980740Recruiting

Video-Tumorboard PLUS

Role: collaborator

NCT03834922Completed

Providing Standardized Consented PROMs (Patient Reported Outcome Measures) for Improving Pain Treatment

Role: collaborator

NCT03429816Not ApplicableCompleted

OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma

Role: collaborator

NCT05662904Phase 1Not Yet Recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML

Role: collaborator

NCT03705403Phase 2Terminated

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

Role: collaborator

NCT06770803Not ApplicableNot Yet Recruiting

High Versus Low Pneumoperitoneum PressUre for Parenchymal Transection in Minimally Invasive Major Liver Surgery

Role: collaborator

NCT06658379Recruiting

Prospective Validation Study of the CD8+TEMRA Cells As a Prognostic Biomarker of Healing Outcome After Fracture

Role: collaborator

NCT01633502Not ApplicableCompleted

Danish Cardiogenic Shock Trial

Role: collaborator

NCT06250686Not ApplicableRecruiting

Exercise and Nutrition Intervention in Ovarian Cancer

Role: collaborator

NCT01281735Recruiting

International Chronic Myeloid Leukemia Pediatric Study

Role: collaborator

NCT02140242Phase 3Completed

Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML

Role: collaborator

NCT03549351Terminated

Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival

Role: collaborator

NCT05082389Completed

Prediction of Hospital Readmissions in SAPV (Specialised Home Palliative Care) Patients

Role: collaborator

NCT02212015Phase 2Terminated

Evaluation of Votrient in Angiosarcoma

Role: collaborator

NCT04819074Unknown

Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms

Role: collaborator

NCT03080792Not ApplicableTerminated

Pre-Exercise for Allogeneic Stem Cell Transplant Patients

Role: collaborator